Brent Willis Joins Vascular Technologies Inc and Ultroid Technologies Inc As New Chief Executive Officer
St. Petersburg, FL (PRWEB) July 8, 2008 -- Vascular Technologies Inc. and Ultroid Technologies, Inc., announce today that Brent Willis, former CCO of InBev and CEO of Cott Corporation, is appointed as Chief Executive Officer and member of the Boards of directors, effective immediately. Vascular Technologies, Inc. is the owner of the new Ultroid® medical device that has shown over 90% effectiveness in the treatment of hemorrhoids, which affect more than 75% of the world's over-50 population. Unlike current surgical treatments, it is painless and outpatient with immediate recovery, and has likely application for the treatment of other varicose veins and spider veins.
"We are very pleased to welcome Brent to the Company and feel extremely fortunate to have someone of his caliber join our firm. He has extensive global experience and a twenty-year track record of delivering superior business performance in highly competitive and difficult environments," commented Michael Cao, Chairman of the Board of Directors. "The Board believes that Brent's leadership will be the lynchpin to take the Ultroid® system to the next level through expanded sales and distribution, capturing the system's full potential in a multi-billion dollar segment."
Prior to joining Vascular Technologies, Inc. and Ultroid Technologies, Inc., Mr. Willis was the Chief Executive Officer for Cott Corporation (COT), the President of Asia Pacific and CCO for InBev (INB.BR), where he led the transformation of the Company into the world's largest brewer. Willis has also been a President in Latin America for the Coca-Cola Company (KO) and a Vice-President at Kraft Foods (KFT), where he started his business career following distinguished service in the United States Army. He holds a Masters of Business Administration from the University of Chicago and a Bachelor of Science in Engineering from the United States Military Academy at West Point.
"I am extremely excited to join Vascular Technologies and Ultroid®, and grow the Company from near inception to real significance while doing something good at the same time. Ultroid® is a far superior treatment and far more cost effective technology for a condition that affects most of the world's aging population. Expanding Ultroid® to meet that need is an opportunity too interesting to pass up," said Willis.
About Vascular Technologies and Ultroid Technologies
Vascular Technologies, Inc. is one of the fastest growing medical device companies in the United States. Its principal product is the breakthrough Ultroid® Medical System, a less expensive and more effective treatment than current procedures for the treatment of hemorrhoids with new applications for other varicose and spider veins. Ultroid® is a painless, non-invasive outpatient treatment with an over 90% effective rate that replaces ineffective over-the-counter creams and painful surgeries that can be accompanied by infection and prolonged recovery. The Ultroid® procedure can be performed by any physician, regardless of specialty, in their office, in approximately 10-15 minutes. Patients are able to resume their normal daily activities immediately, versus the several month recovery often associated with current laser and other surgical treatments. Ultroid® is FDA-cleared and accepted by most insurers and Medicare.
The Company's website is http://www.Ultroid.com. The brand names referenced in this press release are trademarks of Vascular Technologies, Inc. and Ultroid® Technologies, Inc. its affiliated companies, customers, or other third parties. The Company manages web video-enabled training clinics and markets and manufactures the Ultroid® Medical Devices.
Safe Harbor Statements
This press release may contain forward-looking statements reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
###
Related Themes:
Cardiovascular Training - From the Heart!
Cardiovascular training, or aerobics, requires a different approach than other body parts. At the "heart" of cardiovascular training is one basic premise: if you elevate your heart rate to 65-80 percent of your maximum and keep it there for a period of at least 12 minutes it will stimulate the production of fat-burning enzymes.
Fat Burning Cardio Workouts with Heart Rate Monitors
When it comes to weight loss the first thing many people think about is that they have to do tons of cardio. Many people spend hour after hours counting the calories burned on their treadmill. Others are using a heart rate monitor to stay in their fat burning zone for hours hoping the fat will burn away. One of the number one questions I get is "I do 6 hours of cardio a week and can't lose a pound." With proper hear rate monitor training, a person can optimize their workout to raise their metabolism and burn more fat not just during your workout, but all day long.
New Cardiovascular Devices Will Improve Treatments for Vascular Disease Including Stroke, According to a New Report from MedDevice Concepts
Cardiovascular ultrasound therapy sales will approach $400M in five years, according to a new report from MedDevice Concepts. The number of procedures will grow at a compound rate of 46% per year. By 2011, 177,000 patients will be treated with the new devices, few of which are commercially available today.
Cardio Enthusiasts: Discover a More Effective Training Method for Fat Loss and Heart Health!
It is common to hear fitness professionals and medical doctors prescribe low to moderate intensity aerobic training (cardio) to people who are trying to prevent heart disease or lose weight. Most often, the recommendations constitute something along the lines of "perform 30-60 minutes of steady pace cardio 3-5 times per week maintaining your heart rate at a moderate level".
Natural Cardio Cleansing Program Designed to Reverse Heart Disease Without Drugs is Detailed in Pioneering Heart Health Manual
The latest title from Truth Publishing offers real heart attack prevention the natural way: The Weiss Method is a detailed, easy to follow 'owners manual' for the heart.
Health And Fitness Essentials ? The Cardio-Vascular Workout.
To accomplish a good cardio-vascular workout all you really need is a good pair of running shoes. Most cardio-vascular exercise needs little or no third party apparatus to help you accomplish your routine. Running, dancing, walking can all be done with no equipment (well, if dancing, then maybe some music would help). Other forms of cardio are step, circuit training, bike riding, swimming, aerobics and more...
New JACC Analysis Details Cardiovascular Protective Benefits of Carvedilol In Heart Failure Patients
Carvedilol benefits in heart failure patients.
Real Time Vascular Fluorescence is the Biggest Advance in Intra-Operative Vascular Neurosurgery in Years
Leica Microsystems has received an FDA 510(k) clearance for the Leica FL800, an intra-operative video angiography device for the viewing of blood flow in the cerebral vascular area using Akorn ICG. This is the only FDA (U.S. Food and Drug Administration) clearance for video angiography in the cerebral vascular area using ICG (IndoCyanine Green) as a fluorescent agent.
Primary Certificate in Vascular Surgery is Watered Down, Says Head of International Vascular Surgery Body
Sir Peter R.F. Bell, MD, President of the International Society for Vascular Surgery (ISVS), delivered a powerful and poignant speech today at the 33rd annual VEITHsymposium, a premier global Vascular Surgery conference, regarding the primary certificate for Vascular Surgery.
Brent Willis Joins Vascular Technologies Inc and Ultroid Technologies Inc As New Chief Executive Officer
Brent Willis Joins Vascular Technologies Inc and Ultroid Technologies Inc As New Chief Executive Officer.
New Body Needed: Benefits Of Cardio Workouts For Weight Loss And Heart Health
Are you concentrating on the physical aspects when contemplating the best cardio workout for weight loss? Don't stop there! Once you discover the psychological benefits, you will become hooked on fitness. Countless studies have proven the mood-enhancing effects of a 20 or 30 minute workout. From teens to seniors will experience this uplifting, invigorating result. Geared to create your new body? Ready to get ripped to burn belly fat? Let's see why a cardio workout for weight loss delivers the goods every time.
High Carbs/Low Fat Diets and Cardio Vascular Disease
For the past 20 years, the American public has been bombarded with the
message: "Fat is bad!" As a result, our food supply is now inundated with "low
fat" foods, engineered foods and foods processed to remove natural fats. In
every instance, low fat foods are loaded with carbohydrates.
The Heart Center of MetroWest and Metrowest Medical Center Announce "Cardiovascular Series"
The Heart Center of MetroWest and Metrowest Medical Center present a series of patient lectures on the topic of cardiovascular procedures and conditions in Framingham MA. Lectures will begin Jan 31 2008 with lectures being held monthly through March. Following the dates of the lectures the material will also be available to view on line at their website The Heart Center of MetroWest (http://www.hcmw.com).
New Device for Treating Aneurysms in Portneuf Heart & Vascular Surgeons Hands
The Food and Drug Administration (FDA) approved the Talent Abdominal Stent Graft System on April 16, 2008 and the device is still in a limited market release. Since the FDA's approval, only nine Talent Abdominal devices have been implanted in the Northwest region - three of them by Drs DeLaRosa and Vasquez this past week in Pocatello, Idaho.
Aspirus Heart & Vascular Institute First in Wisconsin to Implant Coapsys Heart Device
Aspirus Heart & Vascular Institute cardiac surgeon Fernando A. Riveron, M.D. recently became the first physician in Wisconsin to implant the Myocor® Coapsys System to treat mitral regurgitation, an increasingly common heart problem. Aspirus is participating in a clinical trial testing the device's ability to repair dysfunctional mitral valves without stopping the patient's heart during surgery.
